News
25th May 2026
Intergen Genetics and Immunosis Announce Partnership to Advance RNA-Based Diagnosis for Patients with Immune Dysregulation
Intergen Genetics has announced a strategic partnership with Immunosis to develop and commercialise advanced RNA-based diagnostic technology for patients with immune dysregulation, aiming to significantly reduce time to diagnosis and enable earlier, more targeted treatment decisions.
This partnership addresses a critical unmet need by combining Immunosis’ proprietary RNAinsights platform capable of detecting immune dysfunction at a functional, molecular level with Intergen Genetics’ established clinical laboratory and R&D infrastructure, and regional delivery capabilities. Together, the companies are creating a scalable pathway to bring next-generation immune diagnostics into routine clinical practice across the Middle East and North Africa (MENA).
The first product to be commercialised under the partnership, PrimDx, has been developed by Immunosis for patients with Primary Immunodeficiency (PID). Built on the RNAinsights platform, PrimDx uses advanced transcriptomic analysis to identify patterns of immune dysregulation that may not be detectable through DNA testing alone. In clinical studies involving 180 participants, PrimDx demonstrated an overall diagnostic accuracy of 95%, highlighting its potential to improve diagnostic confidence and reduce the need for prolonged diagnostic journeys.
Under the agreement, Intergen Genetics will lead the commercialisation of PrimDx across the MENA region, with the first phase of rollout expected to begin in 2026. The partnership is designed to expand access to cutting-edge genomic and immune-based diagnostics, supporting clinicians in making faster, more informed decisions and improving outcomes for patients with rare and complex immune conditions.
“Patients with primary immunodeficiencies often experience long and challenging diagnostic journeys, sometimes lasting several years. By integrating RNA-based insights into clinical practice, we have the opportunity to transform how these conditions are identified and managed,” said Professor Dr Ceylaner. “This partnership strengthens our ability to deliver comprehensive, clinically actionable diagnostics to patients across our region.”
Dr. Simon Green, CEO of Immunosis, added: “Our RNAinsights platform was designed to uncover functional immune abnormalities that traditional approaches can miss. Partnering with Intergen Genetics allows us to translate this technology into real-world clinical impact at scale, bringing faster, more precise answers to patients and their physicians in a region where access to advanced diagnostics is rapidly evolving.”
In Türkiye, the incidence of Primary Immunodeficiency is estimated at approximately 1 in 10,000 individuals, with diagnosis often delayed by several years due to recurrent infections and limitations in existing diagnostic approaches. Earlier and more accurate detection has the potential to significantly improve patient outcomes and reduce healthcare burden.
About Intergen. Founded in 1999 in Ankara, Intergen Genetic Diseases Diagnosis Research and Application Center Inc. focuses on rare and undiagnosed genetic diseases. Since its establishment, the company has been providing genetic testing and counseling services to thousands of patients annually. Delivering the highest quality sequencing and counselling services, Intergen also drives research and innovation in the field through its R&D activities.
About Immunosis. Immunosis is an Australian-based biotechnology company specialising in advanced immune profiling and precision diagnostics. Its proprietary RNAinsights platform utilises transcriptomic data and AI-driven prediction algorithms to decode immune system function, with its lead product PrimDx focused on improving the diagnosis and management of Primary Immunodeficiency.
25th March 2026
Immunosis to present new clinical trial data demonstrating the clinical utility of PrimDx — a whole blood test for Primary Immunodeficiency.
We’re excited to share that the clinical research for our lead product, PrimDx, has been selected for two presentations at the Clinical Immunology Society (CIS) Meeting in New Orleans (May 6–9, 2026).
🧬 Our abstract, “A Whole-Blood Transcriptomic Assay, PrimDx, Reflects Cellular and Humoral Abnormalities in Primary Immunodeficiency,” has been selected for an oral presentation in the “Future is Here” session. This work will be presented by our Chief Scientific Officer, Professor Ben Cocks.
🧬 A second abstract, “Enhanced Diagnosis of Primary Immunodeficiencies Including Bronchiectasis Cases Using Transcriptomic Artificial Intelligence,” has been selected for a combined poster/oral presentation in the “Postermania” session, presented by Holly Pedersen, Clinical Research and Quality Leader.
Dr Simon Green, Immunosis CEO, said: “PrimDx is the first test to combine transcriptomic data and artificial intelligence to support the diagnosis of immune deficiencies. In our clinical study of 155 participants, PrimDx demonstrated greater than 90% overall accuracy and strong concordance with standard clinical laboratory immune system assessments.”
Professor Jo Douglas, Principal Clinical Investigator at Royal Melbourne Hospital, added: “PrimDx shows strong clinical utility and has the potential to significantly reduce time to diagnosis and improve patient outcomes in Primary Immunodeficiency.”
This clinical trial was conducted in collaboration with leading teams at:
- Royal Melbourne Hospital
- The Royal Children’s Hospital
- Walter and Eliza Hall Institute
We look forward to sharing these results with the clinical immunology community at #CIS2026.
2nd May 2025
Immunosis presents new data at the 2025 Clinical Immunology Society Meeting in Philadelphia
Immunosis presented our new data demonstrating clinical proof of concept to identify patients at risk of Primary Immunodeficiency.
In a clinical study involving 133 participants, our lead product, PrimDx, demonstrated an overall accuracy of 95% for patients with antibody deficiency.
The technology, developed by Immunosis, uses unique gene expression signatures and artificial intelligence algorithms to diagnose patients with diseases caused by defects in the immune system.
Dr. Simon Green, the CEO of Immunosis said "PrimDx offers a paradigm shift for the diagosis and monitoring of patients with immune deficiencies and is designed to improve the lives of patients"
13th February 2025
Immunosis recognised by Forbes magazine as a standout start up biotech company
Immunosis is delighted to be seletected by Forbes Magazine as a standout Australian start up biotechnology company. We were the first resident to move into the Jumar Bioincubator space in the new CSL building.
Dr. Simon Green, the CEO of Immunosis said "it is wonderful being part of such a vibrant ecosystem and so close to our key collarborating partners at the Royal Melbourne Hospital, Royal Children's Hospital and the Walter an Eliza Hall Institute for Medical Research"
The Jumar Bioincubator was founded by Australia’s own CSL, in conjunction with the University of Melbourne, WEHI and Breakthrough Victoria. It is managed by Cicada Innovations.
Here is the link to the article
16th December 2025
Recruitment Open for the IMM003 Trial – A Genomic Study on Bronchiectasis and Primary Immunodeficiency
We’re thrilled to announce that recruitment is now open for the IMM003 Trial: A Pilot Genomic Analysis of Patients with Bronchiectasis and Primary Immunodeficiency (PID).
This study aims to develop an advanced diagnostic method using genetic information to improve the detection of PID. If successful, this test could lead to faster diagnoses, enabling patients to access life-changing treatments and therapies sooner.
Many patients with PID develop bronchiectasis, and this research could significantly enhance our ability to distinguish PID among those with lung disease.
We’re proud to collaborate once again with the incredible teams at the Royal Melbourne Hospital and WEHI to drive this important work forward.
For more information, reach out to any of our Immunosis team.
15th October 2024
Immunosis awarded Stage 2 funding under ANDHealth+ Program
After successful completion of a Stage 1 project to evaluate the clinical utilty, commercial opportunity and market access, Immunosis has been invited to participate in Stage 2 funding. Under the ANDHealth+ program, five of Australia's best digital health companies will share in $3.25m AUD funding, supported by the Medical Research Future Fund (MRFF).
28th May 2024
Immunosis attends Clinical Immunology Society Annual Meeting in Minneapolis to present additional data from clinical study
The entire Immunosis team was in Minneapolis this May to attend the Clinical Immunology Society Annual Meeting. Our CSO, Ben Cocks, presented our results alongside Senior Scientist Emma Gail during a lively poster session. You can read our abstract below or through the Clinical Immunology supplement link:
https://www.sciencedirect.com/science/article/abs/pii/S1521661624001785
25th August 2023
Boost for Immunosis to commercialise diagnosis of diseases driven by immune dysregulation
We are pleased to announce Immunosis has been selected as a recipient of the highly competitive ANDHealth+ award for 2023.
Immunosis is delighted to work with ANDHealth to further develop and commercialise our technology including our lead product, PrimDx, a diagnostic test for patients with primary immunodeficiency.
We are working to establish our RNA-based platform technology for understanding and diagnosing diseases driven by immune dysregulation. As part of the ANDHealth+ program, Immunosis plans to conduct a clinical validation study in Australia and the USA in patients prone to repeated sinus and respiratory infections and develop a reimbursement strategy to offset the cost of testing for patients. These steps are critical for the commercialisation of PrimDx in global markets.
The ANDHealth+ program supports and funds digital health companies such as Immunosis to accelerate commercialisation of their platforms. The program is funded by the Australian Government’s Medical Research Future Fund (MRFF).
For more information, please visit the following link:
Read a statement from our CEO, Simon Green, here as well as about the program: https://www.andhealth.com.au/news/five-promising-digital-health-companies-selected-to-scale-exciting-new-australian-health-technologies
19th June 2023
Immunosis presents latest data at CIS 2023
CSO Prof. Ben Cocks and senior scientist Dr Emma Gail attended the Clinical Immunology conference in St. Louis this year, learning about the latest research in the field and meeting with leading clinicians and researchers. Dr Gail presented the work from our first clinical study in the poster titled “Identifying patients with primary immunodeficiency using statistical modelling of unique genetic signatures from transcriptomic data” You can view the full poster here:
Read our abstract published in the supplement in the May 2023 issue of Clinical Immunology: https://www.sciencedirect.com/science/article/pii/S1521661623002656
29th March 2023
Immunosis presenting and looking to collaborate at CIS 2023
Immunosis' Senior Scientist Dr Emma Gail and CSO Prof Ben Cocks will be attending the 2023 Clinical Immunology Society meeting in St Louis MO USA May 18-21.
Dr Gail will be presenting data on the potential of transcriptomics to better identify and characterise patients with Primary Immune Deficiency (PID).
The new results for our diagnostic test, Prim-Dx, have been generated through collaborations with the Walter and Eliza Hall Institute of Medical Research, Royal Children’s Hospital, Murdoch Children’s Research Institute, and the Royal Melbourne Hospital.
Immunosis CEO Dr Simon Green said “Immunosis are looking forward to welcoming discussion with leading clinicians and investigators on expanding transcriptomic studies for PID complementing other clinical studies".
Abstract is titled: Using statistical modelling to better identify primary immunodeficiency using a unique genetic signature from transcriptomic data
Immunosis has appointed Professor Ben Cocks as Chief Scientific Officer.
2nd June 2022
The Hon Jaala Pulford announced today a grant of $100k to fund clinical trial work with the aim of developing the Immunosis diagnostic technolgy for patients with Primary Immune Deficiency.
Both patients and healthy controls are currently being recruited for the study.
https://www.premier.vic.gov.au/site-4/faster-diagnosis-possible-new-clinical-trial
